Cogent Biosciences Inc Financials
This page shows Cogent Biosciences Inc (COGT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Cogent Biosciences Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Cogent Biosciences Inc generates $0.80 in operating cash flow (-$264.4M OCF vs -$328.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Cogent Biosciences Inc earns $-108.9 in operating income for every $1 of interest expense (-$333.4M vs $3.1M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Cogent Biosciences Inc's EBITDA was -$330.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 21.0% from the prior year.
Cogent Biosciences Inc generated -$266.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 27.7% from the prior year.
Cogent Biosciences Inc reported -$328.9M in net income in fiscal year 2025. This represents a decrease of 28.6% from the prior year.
Cogent Biosciences Inc earned $-2.16 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 11.3% from the prior year.
Cogent Biosciences Inc held $312.0M in cash against $222.9M in long-term debt as of fiscal year 2025.
Cogent Biosciences Inc had 162M shares outstanding in fiscal year 2025. This represents an increase of 46.9% from the prior year.
Cogent Biosciences Inc's ROE was 51.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Cogent Biosciences Inc invested $269.8M in research and development in fiscal year 2025. This represents an increase of 16.0% from the prior year.
Cogent Biosciences Inc invested $1.6M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 171.2% from the prior year.
COGT Income Statement
| Metric | Q4'25 | Q3'25 | Q3'25 | Q3'25 | Q4'24 | Q3'24 | Q3'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | $15.3M+1398.8% | $1.0M-67.5% | $3.1M+2.8% | $3.1M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $69.0M+10.9% | $62.2M-1.3% | $63.0M | N/A | $63.6M+17.2% | $54.3M+3.0% | $52.7M |
| SG&A Expenses | N/A | $14.4M+7.4% | $13.4M+12.4% | $11.9M | N/A | $11.8M+16.9% | $10.1M+4.1% | $9.7M |
| Operating Income | N/A | -$83.4M-10.3% | -$75.6M-0.9% | -$74.9M-3445.2% | $2.2M+103.0% | -$75.4M-17.1% | -$64.4M-3.2% | -$62.4M |
| Interest Expense | N/A | $1.5M+364.6% | $314K | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | -$80.9M-10.1% | -$73.5M-2.1% | -$72.0M-3233.9% | $2.3M+103.3% | -$70.6M-19.8% | -$59.0M-1.0% | -$58.3M |
| EPS (Diluted) | N/A | $-0.50+5.7% | $-0.53-1.9% | $-0.52-842.9% | $0.07+113.5% | $-0.52-20.9% | $-0.43+12.2% | $-0.49 |
COGT Balance Sheet
| Metric | Q4'25 | Q3'25 | Q3'25 | Q3'25 | Q4'24 | Q3'24 | Q3'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $937.6M+120.1% | $425.9M+55.0% | $274.8M-3.2% | $283.8M-13.4% | $327.9M-14.6% | $384.0M-10.7% | $429.9M-9.7% | $476.1M |
| Current Assets | $910.4M+129.2% | $397.2M+62.1% | $245.0M-3.1% | $252.9M-14.7% | $296.5M-13.2% | $341.5M-7.7% | $370.0M-16.3% | $441.9M |
| Cash & Equivalents | $312.0M+149.0% | $125.3M-1.8% | $127.6M+1.3% | $126.0M+28.4% | $98.2M+1.2% | $97.0M+10.0% | $88.2M-59.1% | $215.8M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | $2.0M+127.3% | $880K-41.0% | $1.5M-26.9% | $2.0M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $301.2M+144.0% | $123.5M+3.1% | $119.8M+84.8% | $64.8M-9.5% | $71.6M+3.3% | $69.4M+22.3% | $56.7M+5.5% | $53.8M |
| Current Liabilities | $64.0M+2.7% | $62.2M+6.5% | $58.4M+18.5% | $49.3M-11.5% | $55.7M+5.0% | $53.0M+32.6% | $40.0M+9.0% | $36.7M |
| Long-Term Debt | $222.9M+403.7% | $44.3M+0.7% | $43.9M | N/A | $0 | N/A | N/A | N/A |
| Total Equity | $636.4M+110.4% | $302.5M+95.1% | $155.0M-29.2% | $219.0M-14.6% | $256.3M-18.6% | $314.7M-15.7% | $373.2M-11.6% | $422.3M |
| Retained Earnings | -$1.2B-9.4% | -$1.1B-8.1% | -$1.0B-7.9% | -$931.5M-8.4% | -$859.5M-8.6% | -$791.6M-9.8% | -$720.9M-8.9% | -$662.0M |
COGT Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q3'25 | Q3'25 | Q4'24 | Q3'24 | Q3'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$79.1M-23.1% | -$64.3M-17.9% | -$54.5M+18.0% | -$66.5M-9.8% | -$60.6M-16.5% | -$52.0M-21.7% | -$42.7M+18.7% | -$52.5M |
| Capital Expenditures | $811K+1147.7% | $65K-50.4% | $131K-76.1% | $547K+629.3% | $75K-73.2% | $280K+89.2% | $148K+111.4% | $70K |
| Free Cash Flow | -$79.9M-24.2% | -$64.4M-17.7% | -$54.7M+18.5% | -$67.1M-10.6% | -$60.7M-16.0% | -$52.3M-22.0% | -$42.8M+18.5% | -$52.6M |
| Investing Cash Flow | -$322.8M-108.2% | -$155.0M-1840.1% | $8.9M-87.2% | $69.4M+12.5% | $61.7M+2.5% | $60.2M+171.1% | -$84.6M-8205.8% | $1.0M |
| Financing Cash Flow | $588.7M+170.8% | $217.4M+360.3% | $47.2M+89.1% | $25.0M+95938.5% | $26K-95.8% | $624K+343.8% | -$256K-100.1% | $214.1M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
COGT Financial Ratios
| Metric | Q4'25 | Q3'25 | Q3'25 | Q3'25 | Q4'24 | Q3'24 | Q3'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | 14.6%+1194.7pp | -1180.0%-844.1pp | -335.9%+51.9pp | -387.8% |
| Net Margin | N/A | N/A | N/A | N/A | 15.0%+1183.9pp | -1168.9%-833.8pp | -335.1%+47.8pp | -382.9% |
| Return on Equity | N/A | N/A | N/A | N/A | 7.2% | N/A | N/A | N/A |
| Return on Assets | N/A | -19.0%+7.8pp | -26.8%-1.4pp | -25.4%-30.0pp | 4.7%+23.0pp | -18.4%-4.7pp | -13.7%-1.4pp | -12.3% |
| Current Ratio | 14.23+7.9 | 6.38+2.2 | 4.19-0.9 | 5.13-0.2 | 5.32-1.1 | 6.44-2.8 | 9.25-2.8 | 12.05 |
| Debt-to-Equity | 0.35+0.2 | 0.15-0.1 | 0.28-0.0 | 0.30+0.3 | 0.00-0.2 | 0.22+0.1 | 0.15+0.0 | 0.13 |
| FCF Margin | N/A | N/A | N/A | N/A | -55.3%+947.5pp | -1002.8%-641.3pp | -361.5%+17.1pp | -378.6% |
Similar Companies
Frequently Asked Questions
Is Cogent Biosciences Inc profitable?
No, Cogent Biosciences Inc (COGT) reported a net income of -$328.9M in fiscal year 2025.
What is Cogent Biosciences Inc's earnings per share (EPS)?
Cogent Biosciences Inc (COGT) reported diluted earnings per share of $-2.16 for fiscal year 2025. This represents a -11.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Cogent Biosciences Inc's EBITDA?
Cogent Biosciences Inc (COGT) had EBITDA of -$330.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Cogent Biosciences Inc have?
As of fiscal year 2025, Cogent Biosciences Inc (COGT) had $312.0M in cash and equivalents against $222.9M in long-term debt.
What is Cogent Biosciences Inc's return on equity (ROE)?
Cogent Biosciences Inc (COGT) has a return on equity of 51.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Cogent Biosciences Inc's free cash flow?
Cogent Biosciences Inc (COGT) generated -$266.0M in free cash flow during fiscal year 2025. This represents a -27.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Cogent Biosciences Inc's operating cash flow?
Cogent Biosciences Inc (COGT) generated -$264.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Cogent Biosciences Inc's total assets?
Cogent Biosciences Inc (COGT) had $937.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Cogent Biosciences Inc's capital expenditures?
Cogent Biosciences Inc (COGT) invested $1.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Cogent Biosciences Inc spend on research and development?
Cogent Biosciences Inc (COGT) invested $269.8M in research and development during fiscal year 2025.
How many shares does Cogent Biosciences Inc have outstanding?
Cogent Biosciences Inc (COGT) had 162M shares outstanding as of fiscal year 2025.
What is Cogent Biosciences Inc's current ratio?
Cogent Biosciences Inc (COGT) had a current ratio of 14.23 as of fiscal year 2025, which is generally considered healthy.
What is Cogent Biosciences Inc's debt-to-equity ratio?
Cogent Biosciences Inc (COGT) had a debt-to-equity ratio of 0.35 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Cogent Biosciences Inc's return on assets (ROA)?
Cogent Biosciences Inc (COGT) had a return on assets of -35.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Cogent Biosciences Inc's cash runway?
Based on fiscal year 2025 data, Cogent Biosciences Inc (COGT) had $312.0M in cash against an annual operating cash burn of $264.4M. This gives an estimated cash runway of approximately 14 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Cogent Biosciences Inc's Piotroski F-Score?
Cogent Biosciences Inc (COGT) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cogent Biosciences Inc's earnings high quality?
Cogent Biosciences Inc (COGT) has an earnings quality ratio of 0.80x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Cogent Biosciences Inc cover its interest payments?
Cogent Biosciences Inc (COGT) has an interest coverage ratio of -108.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.